EUCTR2009-016879-29-GB进行中（未招募）1 期
GR015: Randomized double-blind phase III study of NGR-hTNF plus best investigator’s choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM) - NGR015
MOLMED0 个研究点目标入组 400 人开始时间: 2010年10月26日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Age = 18 years
- •2. Histological or cytological confirmed malignant pleural mesothelioma of any of the following subtype: epithelial, sarcomatoid, mixed, or unknown
- •3. Prior treatment with no more than one systemic pemetrexed-based chemotherapy regimen administered for advanced or metastatic disease. Prior use of a biological agent in combination with a pemetrexed-based regimen and prior administration of intrapleural cytotoxic agents are allowed. Patients who have
- •previously received anthracyclines should not receive doxorubicin.
- •4. ECOG Performance Status 0 - 2 (Appendix A)
- •5. Life expectancy of = 12 weeks
- •6. Adequate baseline bone marrow, hepatic and renal function, defined as follows:
- •a. Neutrophils = 1.5 x 109/L; platelets = 100 x 109/L; hemoglobin = 9 g/dL
- •b. Bilirubin = 1.5 x ULN
- •c. AST and/or ALT = 2.5 x ULN in absence of liver metastasis or = 5 x ULN in presence
- •of liver metastasis
- •d. Serum creatinine < 1.5 x ULN
- •7. Measurable or non-measurable disease according to MPM-modified RECIST criteria
- •8. Patients may have had prior treatment providing the following conditions are met:
- •a. Surgery: wash-out period of 14 days
- •b. Systemic anti-tumor and radiation therapy: wash-out period of 28 days
- •9. Patients must give written informed consent to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 390
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 390
排除标准
- •1. Patients must not receive any other investigational agents while on study
- •2. Patients with myocardial infarction within the last six months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
- •3. Uncontrolled hypertension
- •4. QTc interval (congenital or acquired) > 450 ms
- •5. History or evidence upon physical examination of CNS disease unless adequately treated (e.g., primary brain tumor, any brain metastasis, seizure not controlled with standard medical therapy), or history of stroke
- •6. Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol
- •7. Known hypersensitivity/allergic reaction or contraindications to human albumin preparations or to any of the excipients
- •8. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
- •9. Pregnancy or lactation.
研究者
相似试验
进行中（未招募）
1 期
GR015: Randomized double-blind phase III study of NGR-hTNF plus best investigator s choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM) - NGR015Patients with advanced malignant pleural mesothelioma (MPM)previously treated with pemetrexedMedDRA version: 12.1Level: LLTClassification code 10035605Term: Pleural mesothelioma malignant advancedEUCTR2009-016879-29-ITMOLMED390
进行中（未招募）
1 期
Study of efficacy and safety of the compound NGR-hTNF in patient with advanced malignant pleural mesotheliomaEUCTR2009-016879-29-NLMOLMED390
已完成
3 期
GR015: Randomised double-blind phase III study of NGR-hTNF plus best investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM)Pleural Tumor / advanced malignant pleural mesothelioma10027412NL-OMON37673COMPANY IS INNOPHARMA S.R.L, ITALY45
进行中（未招募）
1 期
Study of efficacy and safety of the compound NGR-hTNF in patient with advanced malignant pleural mesotheliomaAdvanced malignant pleural mesothelioma previuosly treated with a pemetrexed based chemotherapy regimenMedDRA version: 15.0Level: PTClassification code 10035605Term: Pleural mesothelioma malignant advancedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-016879-29-BEMOLMED390
进行中（未招募）
1 期
Study of efficacy and safety of the compound NGR-hTNF in patient with advanced malignant pleural mesotheliomaAdvanced malignant pleural mesothelioma previuosly treated with a pemetrexed based chemotherapy regimenMedDRA version: 14.1Level: PTClassification code 10035605Term: Pleural mesothelioma malignant advancedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-016879-29-SEMOLMED390